Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.

Author: AchebeMaureen, AgodoaIrene, AtagaKenneth I, BrownRobert C, El-BeshlawyAmal, GraySarah, HassabHoda, HowardJo, Lehrer-GraiwerJoshua, NdubaVidelis, TondaMargaret, VichinskyElliott

Paper Details 
Original Abstract of the Article :
For decades, patients with sickle cell disease have had only a limited number of therapies available. In 2019, voxelotor (1500 mg), an oral once-daily sickle haemoglobin polymerisation inhibitor, was approved in the USA for the treatment of sickle cell disease in patients aged 12 years and older on ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/S2352-3026(21)00059-4

データ提供:米国国立医学図書館(NLM)

Hope for Sickle Cell Disease: A Long-Term Study

The field of sickle cell disease (SCD) research is always searching for better treatments. This study focuses on a new drug called voxelotor. Voxelotor is an oral medication taken once daily to help prevent red blood cells from clumping together. This study used a randomized, double-blind, placebo-controlled trial design, which is like a scientific treasure hunt where we compare the effects of the real drug with a fake one (the placebo), while the participants don’t know which they are getting. The researchers wanted to see how well voxelotor worked and how safe it was over a long period of time. They found that voxelotor continued to be effective and safe in treating SCD after 72 weeks. This is a really important finding because it shows that voxelotor might be a long-term solution for people living with SCD.

Voxelotor: A New Dawn for SCD Treatment

This long-term study showed that voxelotor is a promising treatment option for SCD. It’s like finding a cool oasis in the vast desert of SCD treatments. The results suggest that voxelotor can effectively improve the lives of people living with SCD.

Managing SCD: What You Need to Know

SCD is a chronic condition, meaning it lasts a long time. It’s important to stay in touch with your doctor and follow their instructions carefully to manage your condition. Voxelotor might offer hope for a better future for people with SCD, but remember that the best way to manage any health condition is with a team effort – your doctor, your family, and you!

Dr.Camel's Conclusion

This study offers hope for people living with sickle cell disease. Voxelotor shows promising results for long-term treatment, providing a potential oasis in the desert of SCD research. Remember, as with any health journey, it’s important to work with your doctor and maintain a healthy lifestyle. Let’s keep moving forward, one step at a time, towards a healthier future.

Date :
  1. Date Completed 2021-05-03
  2. Date Revised 2021-05-03
Further Info :

Pubmed ID

33838113

DOI: Digital Object Identifier

10.1016/S2352-3026(21)00059-4

Related Literature

Article Analysis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.